You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)腫瘤藥啟動臨床試驗
阿思達克 01-20 09:19
和黃醫藥(00013.HK)公布,在中國啟動一項HMPL-653 的I期臨床試驗。HMPL-653是一種研究性的新型、高選擇性及強效的小分子集落刺激因子-1受體(CSF-1R)抑制劑,旨在作為單藥療法或與其他藥物聯合用於治療惡性腫瘤。首名患者已於1月18日接受給藥治療。 該項I期研究是一項多中心、開放標籤、單臂的臨床試驗,旨在評估HMPL-653治療晚期或轉移性實體瘤和腱鞘巨細胞瘤(TGCT)患者的安全性、耐受性、藥代動力學和初步療效。研究的劑量遞增及劑量擴展階段預計招募約110名患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account